First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Gemcitabine plus cisplatin is standard treatment for advanced urothelial cancer. Ipilimumab
has shown intriguing activity as neoadjuvant therapy in patients with clinically localized
bladder cancer undergoing radical cystectomy. The combination of gemcitabine, cisplatin, plus
ipilimumab may build on the chemosensitivity of urothelial carcinoma to produce more durable
responses and improved outcomes.